Table 3 Multiple logistic regression aimed to identify possible independent predictors of achievement of inactive disease (ASDAS-ID: ASDAS < 1.3) or remission (DAS28 < 2.6) after 52 weeks of treatment with Secukinumab in the whole cohort of patients with AS or PsA.
Variable | β value | Standard error (SE) | Odds ratio (OR) | 95% profile likelihood confidence interval (CI) | P value |
|---|---|---|---|---|---|
Age (above median) | -0.8037 | 0.5448 | 0.4477 | 0.1474 to 1.274 | 0.1402 |
Body weight (above median) | -0.1398 | 0.5536 | 0.8695 | 0.2879 to 2.570 | 0.8006 |
Disease duration (above median) | -0.8409 | 0.5687 | 0.4313 | 0.1372 to 1.304 | 0.1392 |
Male gender | 1.641 | 0.7426 | 5.161 | 1.347 to 26.63 | 0.0271 (*) |
Concomitant use of MTX | 0.1278 | 0.7524 | 1.136 | 0.2576 to 5.172 | 0.8651 |
Previous treatment with TNFi | -0.7003 | 0.7168 | 0.4965 | 0.1201 to 2.101 | 0.3286 |
Highest disease activity status at baseline | -0.3904 | 0.7162 | 0.6768 | 0.1491 to 2.626 | 0.5857 |
Diagnosis of PsA | 0.2529 | 0.6994 | 1.288 | 0.3137 to 5.145 | 0.7177 |